When a clinician in Jamaica, Trinidad, Barbados, or Guyana checks a drug interaction, the tool they are most likely using was built for the United States or United Kingdom market. Drugs and Lactation Database, Lexicomp, Micromedex, even the freely accessible interaction checkers embedded in clinical reference apps — these are built around formularies that do not accurately reflect what is available, commonly prescribed, or regionally relevant in the Caribbean.
The practical consequence is twofold. First, clinicians encounter alerts for drug combinations that involve medicines their patients are unlikely to ever receive in the Caribbean context — generating noise that erodes the clinical usefulness of the alert system. Second, and more significantly, interactions involving drugs that are commonly used in the Caribbean but less prominent in North American or European prescribing practice may receive less robust coverage in those databases.
ElesRx was developed to address this directly. It is a clinical decision support tool built specifically for Caribbean prescribing practice, maintained on a database — pharmacoai — populated with reference to the medicines actually used in the region.
The Formulary Gap — What It Looks Like in Practice
The Problem with US/UK Databases
US databases include thousands of drugs approved by the FDA that are not registered or widely available in Caribbean territories. Alerts referencing these drugs are irrelevant in a Caribbean clinical setting. Conversely, some medicines commonly used in the Caribbean — older generic formulations, regionally distributed products — receive less comprehensive interaction coverage in databases built around a US brand-name formulary.
The ElesRx Approach
The pharmacoai database is populated with reference to medicines available and commonly prescribed in the Caribbean region. Interaction data is sourced from DailyMed and LiverTox — both US public domain — but drug selection and clinical prioritisation reflects Caribbean prescribing practice rather than the US market. The result is a more relevant signal for Caribbean clinicians.
What ElesRx Checks
ElesRx is not a simple pairwise interaction lookup. The clinical decision support functions currently available cover several dimensions of prescribing safety that are relevant to Caribbean practice.
| Function | Clinical Relevance |
|---|---|
| Drug-drug interaction checking | Bidirectional interaction checking across the patient's full medication list. Severity classification and mechanism included with each alert. |
| Prescribing cascade detection | Identifies patterns where a drug prescribed to manage the side effect of another drug may itself be causing harm. Forty-five cascades across six clinical themes currently mapped. |
| ElderWatch — Beers Criteria screening | Flags drugs from the AGS Beers Criteria that are potentially inappropriate in patients aged 65 and over. One hundred and thirty-two drugs currently covered. Particularly relevant given the high burden of polypharmacy in older Caribbean patients. |
| Anticholinergic burden scoring | Calculates the cumulative anticholinergic burden of a patient's medication list using the Anticholinergic Cognitive Burden scale. Clinically significant in older patients at risk of cognitive impairment. |
| Therapeutic duplicate detection | Identifies cases where two drugs from the same class are prescribed simultaneously without clinical justification — a common source of unintended duplication in complex regimens. |
| CYP enzyme interaction flagging | Flags interactions mediated through cytochrome P450 enzyme pathways — the mechanism behind many clinically significant drug interactions that are not always immediately apparent from drug class alone. |
The Caribbean Polypharmacy Context
Polypharmacy — the concurrent use of five or more medications — is a significant and growing clinical challenge across the Caribbean. Non-communicable disease burden in the region is high: hypertension, type 2 diabetes, and dyslipidaemia are prevalent, commonly co-occurring, and each managed with multiple agents. Patients with two or three concurrent NCDs routinely carry medication lists of eight to twelve drugs, often prescribed across multiple prescribers who may not have visibility of each other's contributions to the regimen.
This is the clinical environment in which a drug interaction checker is most needed and most used. It is also the environment in which the limitations of a US-calibrated tool are most apparent — because the specific drug combinations most common in Caribbean NCD management are not necessarily the combinations that received the most attention in a database built around US prescribing patterns.
What ElesRx Is Not
Scope and Limitations — Important
- ElesRx is a decision support tool, not a prescribing authority. It provides information to inform clinical judgment — it does not replace it. The prescribing clinician retains full responsibility for every prescribing decision.
- The database is under active development. Caribbean clinical pharmacology is an evolving field and the pharmacoai database is updated continuously. No interaction database is complete — ElesRx is no exception.
- ElesRx does not cover all Caribbean territories equally. The initial focus is on medicines available across the English-speaking Caribbean. Coverage of territory-specific formulary variations is ongoing.
- ElesRx does not replace a clinical pharmacist. Complex polypharmacy cases warrant pharmacist review regardless of what an automated checker reports. ElesRx is a screening tool, not a comprehensive medication review service.
Access and the Clinical Reports Series
ElesRx is accessible at elesrx.com. The tool operates on a freemium model — core interaction checking is available to registered Caribbean clinicians without a subscription. Advanced functions and full access to the clinical reports series require a subscription.
The ElesRx clinical reports series — the Caribbean Essential Medicines Atlas — covers twenty-four drug classes and clinical themes relevant to Caribbean prescribing practice. These are separate from the interaction checker itself and represent a reference resource for clinicians managing the specific conditions and drug classes most prevalent in the region. Reports one through ten are currently available; the full series of twenty-four reports is being deployed progressively.
ElesRx — Clinical Decision Support for Caribbean Clinicians
Drug interaction checking, polypharmacy screening, and clinical resources built for the Caribbean formulary.
Access ElesRx